Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 1/20 | 0.55 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.52 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.52 |
| ▸ | ACHE | P22303 | 2/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | KCNK3 | O14649 | 3/20 | 0.48 |
| ▸ | KCNK9 | Q9NPC2 | 2/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL312610 | 0.86 | ACHE (0.62) | PARP1HDAC8HDAC6ACHESMN1; SMN2 | |
| SCHEMBL12164013 | 0.85 | PARP1 (0.60) | PARP1HDAC8HDAC6ACHESMN1; SMN2 | |
| SCHEMBL29137265 | 0.85 | PARP1 (0.55) | PARP1HDAC8HDAC6ACHESMN1; SMN2 | |
| SCHEMBL855152 | 0.84 | PARP1 (0.59) | PARP1HDAC8HDAC6SMN1; SMN2KCNK3 | |
| SCHEMBL10526131 | 0.83 | PARP1 (0.53) | PARP1HDAC8HDAC6ACHESMN1; SMN2 | |
| SCHEMBL16682384 | 0.83 | PARP1 (0.53) | PARP1HDAC8HDAC6ACHESMN1; SMN2 | |
| SCHEMBL19267581 | 0.82 | ACHE (0.68) | HDAC6ACHE | |
| SCHEMBL11065475 | 0.82 | PARP1 (0.57) | PARP1HDAC8HDAC6SMN1; SMN2KCNK3 | |
| SCHEMBL29429340 | 0.82 | PARP1 (0.57) | PARP1HDAC8HDAC6SMN1; SMN2KCNK3 | |
| SCHEMBL5752148 | 0.80 | PARP1 (0.50) | PARP1HDAC8HDAC6ACHESMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150119576-A1 | METHOD FOR PRODUCTION OF 3-HYDROXYPROPAN-1-ONE COMPOUND, METHOD FOR PRODUCTION OF 2-PROPEN-1-ONE COMPOUND AND METHOD FOR PRODUCTION OF ISOXAZOLINE COMPOUND | NISSAN CHEMICAL CORPORATION (JP) | 2015-04-30 | — | — | US | disclosed |
| US-8952175-B2 | Method for production of 3-hydroxypropan-1-one compound, method for production of 2-propen-1-one compound and method for production of isoxazoline compound | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2015-02-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150119576-A1 | METHOD FOR PRODUCTION OF 3-HYDROXYPROPAN-1-ONE COMPOUND, METHOD FOR PRODUCTION OF 2-PROPEN-1-ONE COMPOUND AND METHOD FOR PRODUCTION OF ISOXAZOLINE COMPOUND | ADH1C, ADH1A, CYP2E1 | PARP1 1469/4885HDAC8 3098/4885HDAC6 2883/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.